Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Amit Joshi"'
Autor:
Anuradha Chougule, PhD, Pratik Chandrani, PhD, Vanita Noronha, MD, DM, Priyanka Pange, BSc, Shrutikaa Kale, MSc, Ankita Nikam, MSc, Kavya Nambiar, MSc, Dipika Marchande, BSc, Arpana Durve, BSc, Vinod Gupta, BSc, Vinita Jagtap, MSc, Priyanka Tiwrekar, BA, Nandini Menon, MD, DM, Amit Joshi, MD, DM, Rajeev Kaushal, MD, Trupti Pai, MD, Vijay Maruti Patil, MD, DM, Amit Dutt, PhD, Shripad Dinanath Banavali, MD, Kumar Prabhash, MD, DM
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 11, Pp 100566- (2023)
The significance of EGFR targeted therapy in the lung adenocarcinoma is paramount. Several controlled clinical trials have reported considerable survival of EGFR mutation positive patients on receiving the EGFR tyrosine kinase inhibitor (TKI). Howeve
Externí odkaz:
https://doaj.org/article/43043fa0334043ed8be10de1c26073d8
Publikováno v:
South Asian Journal of Cancer, Vol 5, Iss 3, Pp 95-103 (2016)
Smoking tobacco, both cigarettes and beedis, is the principal risk factor for causation of lung cancer in Indian men; however, among Indian women, the association with smoking is not strong, suggesting that there could be other risk factors besides s
Externí odkaz:
https://doaj.org/article/b65125406a0142ce9d07cb7b9105bda4
Autor:
Vijay Patil, Sadaf Mukadam, Srushti Shah, Atanu Bhattacharjee, Kumar Prabhash, Sandeep Ishi, Amit Joshi, Sadhana Kannan, Vanita Noronha, Nandini Menon, Kamesh Maske
Publikováno v:
Chest. 157:1647-1655
Background Although cough is a common and distressing symptom in patients with lung cancer, there is almost no evidence to guide treatment. Aprepitant, a centrally acting neurokinin-1 inhibitor, significantly decreased cough frequency in a pilot stud
Autor:
Kumar Prabhash, Anuradha Chougule, Vichitra Behel, Nandini Menon, Rajiv Kumar, Vijay Patil, Amit Joshi, Vanita Noronha, Pratik Chandrani, Abhishek Mahajan, Vaishakhi Trivedi, Amit Janu, Akhil Kapoor
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 3, Iss 1, Pp 44-50 (2020)
Background: There is a scarcity of data to guide the management of older patients with cancer. We therefore conducted this study to compare the outcomes and toxicities in older versus younger patients with an epidermal growth factor receptor (EGFR)-p
Autor:
Arun Chandrasekharan, Rajiv Kumar, Nikhil Pande, Amit Janu, Nilendu Purandare, Vanita Noronha, Supriya Goud, Kumar Prabhash, Sucheta More, Amit Joshi, Vijay Patil, Vijai Simha, Atanu Bhattacharjee, Abhishek Mahajan, Sadhana Kanan, Vivek Agarwala, Anuradha Chougule
Publikováno v:
Oncotarget
Background: We planned to compare pemetrexed maintenance with erlotinib maintenance in non squamous non Epidermal Growth Factor Receptor (EGFR) mutated non small cell lung cancer (NSCLC). The null hypothesis for this study was that there would be no
Autor:
Vijay Patil, Kanteti Aditya Pavan Kumar, Gunjesh Kumar Singh, Atanu Bhattacharjee, Kumar Prabhash, Nandini Menon, Sadhana Kannan, Satvik Khaddar, Hollis Dsouza, Vanita Noronha, Vichitra Behel, Amit Janu, Nilendu Purandare, Supriya Goud, Abhinav Zawar, Sujay Srinivas, Amit Kumar, Rahul Ravind, Arun Chandrasekharan, Anuradha Chougule, Vaishakhi Trivedi, Dilip Harindran Vallathol, Sudeep Das, Amit Joshi, Abhishek Mahajan, Swaratika Majumdar, Sucheta More
Publikováno v:
EClinicalMedicine
Background Prolonged infusion of low dose gemcitabine (PLDG) in combination with platinum has shown promising activity in terms of improved response rate and progression free survival (PFS); especially in squamous non-small cell lung cancer (NSCLC).
Autor:
Atanu Bhattacharjee, Anant Ramaswamy, Vijay Patil, Nandini Menon, Nikhil Pande, Ashay Karpe, Arun Chandrasekharan, Anuradha Chougule, Abhishek Mahajan, Vanita Noronha, Amit Joshi, Vikas Talreja, Alok Goel, Kumar Prabhash, Amit Janu, Nilendu Purandare
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 2, Iss 1, Pp 21-27 (2019)
Background:> In an open-label, Phase III randomized study, gefitinib was found to be superior to pemetrexed-platinum in terms of progression-free survival in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. In
Autor:
Priyanka Tiwrekar, Vijay Patil, Amit Joshi, Kumar Prabhash, Vanita Noronha, Leena Solanki, Vaishakhi Trivedi, Rohit Dusane, Shruti Kate, Anuradha Chougule
Publikováno v:
Lung Cancer: Targets and Therapy. 10:1-10
Background The significance of uncommon EGFR mutations in newly diagnosed advanced non-small-cell lung cancer (NSCLC) patients is incompletely known. We aimed to analyze the demographic profile, outcome, and treatment attributes of these patients. Pa
Autor:
Anant Ramaswamy, Kumar Prabhash, Vikas Talreja, Avinash C. Pandey, Rajiv Kumar, Nikhil Pande, Vanita Noronha, Ashay Karpe, Amit Joshi, Supriya Goud, Vijay Patil, Alok Goel, Amit Janu, Arun Chandrasekharan, Nilendu Purandare, Anuradha Choughule, Abhishek Mahajan, Atanu Bhattacharjee, Sucheta More
Publikováno v:
Indian Journal of Medical and Paediatric Oncology. 39:493-498
Background: There is a paucity of prospective data for patients who progressed after first-line tyrosine kinase inhibitor (TKI) or pemetrexed doublet among epidermal growth factor receptor (EGFR) mutation-positive metastatic non-small cell lung cance
Publikováno v:
Journal of Thoracic Oncology. 16:S412-S413